Evidence map›Paper›PMID 36999595›Full record

ArticleMolecular medicine reports2023

Hesperetin treatment attenuates glycation of lens proteins and advanced‑glycation end products generation.

Yuri Doki, Yosuke Nakazawa, Naoki Morishita, Shin Endo, Noriaki Nagai, Naoki Yamamoto, Hiroomi Tamura, Megumi Funakoshi-Tago

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Yuri Doki *Department of Hygienic Chemistry, Faculty of Pharmacy, Keio University, Tokyo 105‑8512, Japan.
Yosuke Nakazawa *Department of Hygienic Chemistry, Faculty of Pharmacy, Keio University, Tokyo 105‑8512, Japan.
Naoki MorishitaR&D Division, Hayashibara Co., Ltd., Okayama 702‑8006, Japan.
Shin EndoR&D Division, Hayashibara Co., Ltd., Okayama 702‑8006, Japan.
Noriaki NagaiDepartment of Advanced Design for Pharmaceuticals, Faculty of Pharmacy, Kindai University, Osaka 577‑8502, Japan.
Naoki YamamotoRegenerative Medicine Support Promotion Facility, Center for Research Promotion and Support, Fujita Health University, Toyoake, Aichi 470‑1192, Japan.
Hiroomi TamuraDepartment of Hygienic Chemistry, Faculty of Pharmacy, Keio University, Tokyo 105‑8512, Japan.
Megumi Funakoshi-TagoDepartment of Hygienic Chemistry, Faculty of Pharmacy, Keio University, Tokyo 105‑8512, Japan.
Keio University · JPHayashibara (Japan) · JPFujita Health University · JPKindai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced glycation end products (AGEs) in lens proteins increase with aging, thus inducing cataracts and/or presbyopia. Hesperetin (Hst), which is an abundant plant flavanone largely derived from citrus species, and its derivatives attenuate cataracts and presbyopia

Indexed as

CataractCrystallinsPresbyopiaAnimalsGlycation End Products, AdvancedHesperidinHumansMaillard ReactionMiceCrystallinsGlycation End Products, AdvancedhesperetinHesperidinadvanced glycation end producthesperetinlens proteinnatural flavonoidpresbyopia

Identifiers

PMID36999595
PMCPMC10086570
OpenAlexW4361276470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.